Artificial intelligence (AI) technology developer AI Metrics has signed advanced visualization software firm Imaging Biometrics as a global distribution partner for its virtual liver biopsy software.
Designed to provide assessment of chronic liver disease, AI Metrics' virtual liver biopsy software analyzes liver surface nodularity (LSN) on commonly acquired CT images. This noninvasive assessment of nodules on the liver's surface may help clinicians to diagnose and stage chronic liver disease, according to the company.
In addition to helping AI Metrics with software development services, Imaging Biometrics is also assisting the firm in its quest to receive the CE Mark and U.S. Food and Drug Administration 510(k) clearance.
